Skip to main content

Table 2 Univariate and multivariate analyses of influencing factors of prognosis

From: Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

 

Univariable analysis

Multivariable analysis

p value

HR

95% CI

p value

HR

95% CI

Lower

Upper

Lower

Upper

Initial PSA level

0.820

1.020

0.863

1.204

0.157

0.862

0.701

1.059

Initial stage (M0 vs M1)

0.091

0.776

0.578

1.042

0.469

0.876

0.611

1.254

Gleason score (8–10 vs 6–7)

0.848

1.034

0.737

1.450

0.550

0.897

0.629

1.280

Time to CRPC

 < 0.001

0.434

0.304

0.621

0.001

0.521

0.349

0.776

Chemotherapy (yes vs no)

 < 0.001

2.300

1.731

3.057

0.001

1.683

1.232

2.300

Age at baseline (years)

0.600

0.995

0.975

1.015

0.250

1.012

0.992

1.032

PSA level at baseline

 < 0.001

1.958

1.680

2.282

 < 0.001

1.439

1.179

1.755

ALP level at baseline

 < 0.001

5.138

3.509

7.524

0.019

1.827

1.102

3.028

LDH level at baseline

 < 0.001

45.886

23.15

90.953

 < 0.001

12.123

5.343

27.51

  1. PSA prostate-specific antigen, ALP alkaline phosphatase, LDH lactate dehydrogenase, CRPC castration-resistant prostate cancer, HR hazard ratio, CI confidence interval